Three decades of spinal cord injury (SCI) research have made it clear that abundant, long-distance regeneration of injured axons, which might improve function below a lesion site, remains elusive 1 . Numerous extrinsic mechanisms, including an inhibitory extracellular matrix that develops around the site of injury 2,3 , inhibitory myelin-associated proteins 4, 5 , and a lack of growth-promoting factors, such as neurotrophins 6 , in appropriate spatial and temporal gradients for promotion of growth, contribute to failure of axonal regeneration after SCI.
2 weeks before grafting. This 2-week delay after injury is a clinically relevant time period in which humans might be expected to medically stabilize before undergoing neural stem cell therapy. On the day of grafting, the spinal cord lesion site was surgically re-exposed, and scar tissue on the dorsal aspect of the spinal cord was incised (Fig. 1b,c) . Viscous fluid containing cellular debris was released from the lesion site, and the open lesion cavity was microscopically visualized in its entirety and freed of internal adhesions if present. A total of 20 million cells were then grafted into the lesion cavity using sterilized 100-µl pipettors held freehand. Grafted cells were GFP-expressing human multipotent neural progenitor cells isolated from an 8-weekold human embryonic spinal cord and maintained as a stable cell line (566RSC-UBQT line) [28] [29] [30] . Cells were shipped overnight from Maryland to the University of California, Davis primate research center and arrived on the day of implantation. Immediately before grafting, cells were suspended in a growth factor cocktail and fibrin-thrombin matrix as employed in rodent experiments 17, 18 (Online Methods).
Development of grafting methods
Highlighting the vital importance of large animal models in translational studies, our initial efforts to transplant human neural progenitor cells into four monkeys failed to support graft survival despite use of methods that were successful in rodents. First, we found that cerebrospinal fluid (CSF) rapidly filled the lesion cavity and washed away grafted cells despite the use of a rapidly gelling fibrin-thrombin matrix. Thus, the first two subjects had no surviving cells. Employing a historical method for draining CSF in humans, we tilted the operative table to a 30° angle immediately before grafting to drain CSF from the cervical spinal cord in all subsequent monkeys; this action provided a 15-min period in which the lesion cavity was free of CSF. We also increased the fibrin-thrombin concentration in the grafting mixture to generate rapid gelling (within 3 s). These measures resulted in filling of the lesion site with cells at the conclusion of the grafting session in the next two subjects. However, when examined 2 months later, cells failed to fill the entire lesion cavity, although some graft cell survival was evident. Monkeys up to this point had been immunosuppressed with low initial doses of mycophenolate mofetil and tacrolimus (Online Methods). Beginning with Subject 5, we adopted a more robust immunosuppressive regimen to prevent rejection of the clinically transplanted organ. It comprised higher initial doses of mycophenolate mofetil and tacrolimus and more frequent monitoring (two or three times per week) of immunosuppressant drug levels until therapeutic doses were well established. Using these optimized methods, graft survival and fill of the lesion site were achieved in the five subsequent subjects ( Fig. 1d and Supplementary Fig. 1 ).
Human stem cell grafts survive and extend large numbers of axons over long distances in the lesioned primate spinal cord NPCs in the five subsequent subjects survived in C7 hemisection lesion cavities from 2 through 9 months after grafting ( Fig. 1d and Supplementary Fig. 1 ). Grafts occupied the majority of the lesion cavity in all subjects and integrated well with the host spinal cord. Neuronal markers were readily detectable in grafts at all monitored time points (2-9 months after grafting; Fig. 1 ). The early neuronal marker doublecortin was predominant at 2 months postgrafting and declined but remained detectable after 9 months (Fig. 1g) . The more mature neuronal marker NeuN was also detected at 2 months postgrafting (Fig. 1e,f ) and continued to be expressed over time. The density of cells in the graft was highest at 2 months postimplantation (400,000 cells per mm 3 graft) and steadily dropped 63% to 150,000 cells per mm 3 at 9 months postgrafting (R 2 = 0.93, P = 0.007; Fig. 2a and Table 1 ). In contrast, cell size steadily increased over the same time period (R 2 = 0.82, P = 0.03; Fig. 2b and Table 1 ). Grafts expressed vimentin, a filamentous marker of early astrocytes, at 2 months postimplantation, the earliest time point examined (Fig. 1h) . Glial fibrillary acidic protein (GFAP), a marker of more mature astrocytes, did not detectably colocalize with GFP until 5 months postgrafting (Fig. 1i) , suggesting a prolonged period of astrocyte maturation as well. The relative proportions of cells expressing a marker for one of the three cardinal cell types of the CNS, namely neuronal cells (NeuN), astrocytes (SOX9), and oligodendrocytes (OLIG2), were 57 ± 10%, 26 ± 5%, and 17 ± 7% (mean ± s.e.m.), respectively (Fig. 1e,j,k) ; these proportions were calculated from an analysis of 766 ± 100 (mean ± s.e.m.) individual cells per subject. Astrocyte identity was confirmed in 80% of SOX9 + cells through GFAP colabeling in Subjects 8 and 9 (refs. 31, 32) . Oligodendrocyte lineage was confirmed in all OLIG2 + cells through a lack of colabeling with insulin gene enhancer proteins 1 and 2 (ISL1 and ISL2; data not shown); the lack of graft-derived cell migration (see below) suggests that these cells are likely immature nonmyelinating oligodendrocytes. No graft-derived cells expressed Opalin, a marker of mature myelinating oligodendrocytes 33 (Supplementary Fig. 2 ), (g,h) Labelling for doublecortin (DCX; early neuronal marker; g) and vimentin (early glial marker; h), which were present in all grafts.
(i) Labelling for GFAP (mature astrocyte marker) was only present in 5-and 9-month-old grafts (5-month-old graft shown). Insets of vimentin and GFAP labelling are shown in h and i, respectively, with and without GFP. (j) Labelling for SOX9 (astrocyte and ependymal cell marker), which was present in all grafts (arrows); at 5 and 9 months, 80% of these cells were astrocytes (GFAP + ). (k) Labelling for OLIG2, which was present in all grafts (arrow). (l) Labelling for Ki-67 (a dividing cell marker), which was observed at low (1.5%) but detectable levels (arrow) at all time points. Scale bars: d, 1 mm; e-l, 10 µm. e and f consist of five 0.5-µm confocal optical planes; g, j, k, and l consist of two 0.5-µm confocal optical planes; h and i are single 0.5-µm confocal optical planes.
indicating that mature oligodendrocytes were not yet present in grafts. The proportion of dividing cells in grafts, as assessed through Ki-67 labeling (Fig. 1l) , was low at all examined time points (1.5 ± 0.5%, mean ± s.e.m.); it was 0.7% at 9 months postgrafting. Teratomas or tumors were not detected in any subject. Notably, human axons emerged from grafts in extraordinary numbers and over long distances. Up to 150,000 graft-derived axons were present 2 mm caudal to the lesion 2-9 months postgrafting (Figs. 2 and 3, Table 1 , and Supplementary Fig. 1) , and axons reached distances of up to 50 mm from the graft (Supplementary Fig. 3 ). Axons emerged rostrally in similar numbers and over similar distances (Supplementary Fig. 3 ). Axons extended into white matter tracts that were directly abutted against grafts and appeared to maintain growth within these same white matter fascicles reaching points distant from the graft ( Supplementary Fig. 4) ; this observation suggests that axons may continue to extend through the white matter tracts that they first encounter upon emerging from grafts in the lesion site. Furthermore, the fact that human axons extended linearly through host white matter ( Fig. 3 and Supplementary  Figs. 1, 3 , and 4) suggests that adult myelin does not inhibit the growth of these human axons at this developmental stage, which is a finding consistent with observations in nonprimate models [9] [10] [11] [12] [17] [18] [19] .
Emerging axons expressed class III β-tubulin, a marker of both immature and mature axons; light-chain neurofilament (NF70), a marker of both immature and mature small-diameter axons; and unphosphorylated heavy-chain neurofilament (SMI32), another immature axon marker (Supplementary Fig. 5 ). Graft-derived axons did not express phosphorylated heavy-chain neurofilament (NF200; Fig. 4f, inset) , a marker expressed in many mature human axons (Supplementary Fig. 6 ). Thus, axons were not fully mature even 9 months postgrafting; this is consistent with neuronal size measures and delayed expression of GFAP as noted above and with delayed maturation of other human neural stem cells in rat SCI 34 . Synapse formation was readily detected between graft-derived axons and host neurons in the spinal cord caudal to the lesion site as reflected both by apposition of postsynaptic HOMER1 with presynaptic GFP and synaptophysin and by results from ultrastructural analysis ( Fig. 3 and Supplementary Figs. 7 and 8) . Extending human axons frequently converged onto host motor neurons, wrapping motor neuronal somata with dozens of appositions that colocalized with the synaptic marker synaptophysin (Fig. 3f,g ). Ultrastructurally, all observed graft-host synapses had clear, spheroid vesicles in the presynaptic bouton, and synaptic specializations in the plane of sectioning were characteristically asymmetric, features indicative of an excitatory phenotype (Fig. 3h-j and Supplementary Fig. 8 ), as expected of long-projecting axons 35 . Consistent with the apparent immature state of graft-derived axons, myelination of graft-derived axons that were caudal to the lesion site and up to 1 µm diameter was not detected in the 9 months following grafting (Supplementary Fig. 6 ). In contrast, axons emerging from more rapidly maturing rat neural progenitor cells grafted into rats are readily myelinated by 2 months postimplantation 17 .
Host axons regenerate into human neural stem cell grafts In theory, human neural stem cell implantation into a lesion cavity aims to re-establish a neuronal relay across a site of SCI. For this to occur, host axons must regenerate into neural stem cell grafts, and neural stem cells must extend axons out of these grafts and into the host spinal cord. To assess whether host axons regenerate into human neural progenitor cell grafts, we performed immunolabeling for NF200 (which is not expressed by grafted neurons; Fig. 4f, inset) and serotonergic motor axons, and we performed anterograde tracing of the corticospinal system using intracortical injections of biotinylated dextran amine (BDA). Notably, grafts were extensively and densely penetrated by host NF-200-labeled axons beginning 2 months postgrafting and persisting through 9 months (Fig. 4e,f) . Many NF200-labeled axons originated from intraspinal neuronal circuits. Serotonergic axons, critical for modulation of locomotion, muscle tone, and pain responses 36, 37 , also penetrated grafts (Fig. 4c,d ). The corticospinal projection is the most important neuronal system for voluntary movement in humans, and its regeneration is likely to be important for enhancing voluntary motor movement after human SCI. Yet this is the most refractory axonal system to attempts to elicit axonal regeneration into a lesion site 1 (Supplementary Fig. 9 ). Recently we reported that grafts of neural stem cells driven to a spinal cord identity support regeneration of corticospinal axons in rodent models of SCI 19 . We now report for the first time to our knowledge the regeneration of primate corticospinal axons into human NPC grafts ( Fig. 4a,b) . Corticospinal axons readily crossed the host-graft interface to penetrate distances up to 500 µm into the graft (Fig. 4b) .
Functional outcomes
Monkeys were scored in an open field task that sampled over 25 features of motor function [38] [39] [40] . The scoring system includes several subscales for object manipulation, climbing, and overground locomotion as monkeys engage in naturalistic behaviors in a large testing enclosure [38] [39] [40] (Supplementary Fig. 10 ). Monkeys received points for function in each behavioral category and were given a composite score representing an overall assessment of neurological function. The primate model of C7 lesion was designed to assess potential therapies for improving distal forelimb function, as the neural circuitry for hand control is located in the C7-T1 spinal levels that range 1-20 mm below the lesion, and axons extending from a neural stem cell graft reach these segments (Figs. 2 and 3) . Function among monkeys with nonsurviving grafts (Subjects 1-4) exhibited stability or only partial spontaneous improvement up to 4-8 weeks postinjury but then reached stability without subsequent overall improvement (Supplementary Figs. 10 and 11), a pattern consistent with previous studies in lesiononly (untreated) control subjects 27, 38 (Supplementary Fig. 11 ). In contrast, among monkeys with surviving grafts, the initial 4-to 8-week period of functional loss or partial spontaneous improvement after lesion was followed by a second period of subsequent improvement 10 weeks after lesion (Supplementary Fig. 10 ). Object manipulation scores recovered to >25% success in four of five monkeys with grafts but in only one of four monkeys without grafts. Moreover, peak right-hand object manipulation scores were greater in monkeys with grafts (P < 0.01, Wald chi-square; Supplementary Fig. 10 ). In contrast, the climbing score, which measures both forelimb and hindlimb use, did not differ significantly between monkeys with and without surviving grafts (P = 0.19, Wald chi-square; Supplementary Fig. 10 ). Unlike object manipulation, locomotor recovery is fairly extensive after C7 hemisection in monkeys, as in humans 41 , and values on this subscale differed between groups with surviving and nonsurviving grafts by only 12%, a modest amount that was nonetheless significant (P = 0.05, Wald chi-square; Supplementary Fig. 10 ). Monkeys with surviving grafts exhibited a significant degree of improvement in peak performance in an overall measure of motor function that combines all measures as compared to monkeys without surviving grafts (P = 0.02, Wald chi-square; Supplementary Fig. 10) .
A composite behavioral score was also generated using nonlinear principal component analysis (PCA) on functional outcome data. This demonstrated a significant difference in multidimensional recovery curves between monkeys with surviving grafts relative to those with nonsurviving grafts as determined through a last-observationcarried-forward analysis and linear mixed-model testing (P < 0.05; Supplementary Figs. 10 and 12) . These results are interpreted with caution because the study did not contain a lesioned control group in which no attempt to graft was made and because monkeys with poor graft survival did not live as long as monkeys with surviving grafts Millions of cells survived in all grafts. Up to 155,000 axons emerged from grafts at 2 mm caudal to the lesion site within 3 months of grafting. Axon numbers appeared to be stable from 5 to 9 months following grafting. (Subjects 1-4 were enrolled earlier in the study, and their early euthanization was preplanned for assessment of graft survival). However, three points support the probability that these statistically significant improvements in function in monkeys with surviving grafts reflect true recovery: (i) control lesioned animals from previous 27, 38 and recent ( Supplementary Fig. 11 ) studies did not exhibit late functional recovery of the type observed in successfully grafted monkeys; (ii) one monkey without graft survival in the present study that was perfused after 21 weeks did not show late improvement ( Supplementary  Fig. 10b) ; and (iii) improvements were proportionately greater in measures of forelimb than hindlimb function in successfully grafted subjects, which is consistent with dense penetration of graft-derived axons into cervical spinal cord segments (Fig. 3) .
BDA
Cells do not migrate from the lesion site or form ectopic colonies Previous studies have reported long-distance migration of human neural stem cells implanted into mouse models; this migration has consisted nearly entirely of glia 42 . In this study, we did not observe migration of human neurons or glia more than 100 µm from the lesion site ( Fig. 3 and Supplementary Fig. 1 ). This result is consistent with graft-derived OLIG2 + cells representing immature oligodendrocytes rather than migratory oligodendrocyte progenitor cells 43 . Also, ectopic deposits of grafted neural stem cells have been observed along the spinal cord central canal and on the surface of the spinal cord in rat models 44, 45 . In the present study, we did not observe migration of implanted human neural progenitor cells in the central canal, ventricles, or brain. In one subject, a single colony of GFP-expressing NPCs was present on the spinal cord surface directly at the site of engraftment, but not at more distal sites. Lesions in all nine monkeys were similar in extent ( Supplementary  Fig. 13 ). Grafts were well vascularized as revealed by both Nissl staining and collagen immunolabeling (Supplementary Fig. 14) . Mild perivascular cellular infiltrates consisting of CD8 + T cells were present in fully immunosuppressed monkeys, suggesting that there was an ongoing, low-grade immune response that continued 9 months postgrafting (Supplementary Fig. 14) .
Visualization of grafts by magnetic resonance imaging
We performed high-resolution 3D T1-and T2-weighted isotropic magnetic resonance imaging (MRI) scans on a 3 Tesla Siemens clinical MR scanner in monkeys sedated with ketamine (5 mg per kg body weight) after grafting to determine whether fill of the lesion site could be detected in the living subject. Findings were compared to those from anatomical analyses ( Fig. 1 and Supplementary  Fig. 1 ). Monkeys lacking surviving grafts exhibited a low signal intensity on T1-weighted imaging and a high signal intensity on T2-weighted imaging in the lesion site, whereas monkeys with surviving grafts exhibited the opposite result (Supplementary Fig. 15 ).
DISCUSSION
Four important observations arise from this study. First, human neural stem cells can be successfully engrafted to fill the large lesion cavity of a nonhuman primate spinal cord using methods that are unique to the primate model. These methods include an increased concentration of fibrinogen-thrombin in the grafting mixture and intraoperative drainage of CSF to create a dry grafting cavity. Second, human grafts exhibit a prolonged time period of maturation. Although the grafts continued to mature over the 9-month period of this study, functional effects of the grafts may have been evident 3-4 months postgrafting, when axons have already extended 50 mm into the host. Immature axons and synapses conduct action potentials and are capable of influencing signal processing in the hippocampus 46, 47 ; similarly, active immature graft-derived axons could account for the functional benefits observed herein. Third, unprecedented numbers of new human axons are capable of extending out from the lesion site and into the surrounding spinal cord; up to 150,000 axons extend from the lesion on one side of the spinal cord, a substantial mass of new circuitry that represents a potential mechanism for influencing functional outcomes. Observations of functional outcomes through 9 months following SCI indicate that partial functional recovery occurs. It is possible that longer observation periods could result in greater recovery. Fourth, we describe the regeneration of corticospinal axons, essential for voluntary movement in humans, into a lesion site in a primate model for the first time to our knowledge.
Highlighting the importance of scaling up to larger animal models, we found that grafting methods that were effective in rodent models did not enable graft survival in nonhuman primates. Following several modifications to the rodent grafting technique, including modifications to the grafting matrix, physical measures (operative table tilt to drain CSF), and more extensive immunosuppression, successful engraftment was achieved. Had we or others attempted human translation without prior large animal testing, there would have been a substantial risk of clinical trial failure not because of a lack of biological therapeutic potential for neural stem cells, but as a simple result of graft loss. It is important that translational studies of invasive cellular transplantation avoid these pitfalls and utilize larger animal models when possible 24, 25 .
A key limiting factor in the translational relevance of previous efforts to repair SCI has been limited regeneration of corticospinal axons 48, 49 . Although enhanced sprouting of host axons in spared host gray matter after SCI through manipulation of expression of phosphatase and tensin homolog (PTEN) and suppressor of cytokine signaling 3 (SOCS3) is impressive 50, 51 , these genetic manipulations primarily promoted corticospinal growth in spared regions of the host spinal cord rather than regeneration into spinal cord lesion sites themselves. Yet the majority of human injuries are clinically complete, and it is unclear whether targeting the relatively low number of corticospinal axons in small regions of spared host tissue will be useful 52 . Thus, achieving corticospinal regeneration into a lesion site is likely important in translational human therapies for severe injury 53 . We recently reported that spinal cord replacement with homologous spinal cord neural anlage supports corticospinal axon regeneration into lesion sites in rodents and enhances forelimb reaching function 19 . In the present study, primate corticospinal axons also regenerated into human neural stem cells grafted to lesion sites. Given the critical role of corticospinal systems in human fine motor control, their regeneration represents an important milestone in translational relevance of a primate model. Corticospinal axons regenerated ~0.5 mm into grafts. In future studies, we will determine whether greater distances and densities of corticospinal penetration might be achieved using therapies that enhance the endogenous growth state of host neurons, such as transient treatment with pharmacological PTEN inhibitors 50, 54, 55 .
Grafts exhibited evidence of continuing maturation over time. Astrocytes first expressed the mature marker GFAP at 5 months postgrafting, and neurons continued to exhibit increasing somal size over 9 months. The number of grafted neurons fell by approximately 50% at the longest observed time point, consistent with patterns observed in normal neural development [56] [57] [58] . It is possible that graft neurons that failed to form stable synapses were selectively eliminated 59 . It is important that future human clinical trials take into considerationthe possibility that grafts will mature gradually with potentially late effects on functional outcomes.
Finally, a major barrier to achieving adult axon regeneration has been the inhibitory nature of adult myelin against axon growth 4, 5 . Here we show that axons emerging from human neural stem cells extend abundant axons through white matter, overcoming a major limiting factor in the regeneration field. In parallel, host adult axons regenerated into the myelin-free stem cell environment. Accordingly, neural stem cell therapy represents a means of circumventing one of the major challenges to axon regeneration in the adult CNS.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
ONLINE METHODS

Subjects.
We studied a total of nine male rhesus macaques (Macaca mulatta) aged 6-10 years that had not participated in any previous studies. Post hoc anatomical analyses separated the subjects into two groups according to graft survival (n = 4 monkeys without grafts; n = 5 monkeys with grafts). Our previous work in this model of SCI has demonstrated sufficiently low variability to achieve statistical significance with groups of this size 27 . All surgical and experimental procedures adhered to the principles outlined by the American Association for the Accreditation of Laboratory Animal Care and were approved by the Institutional Animal Care and Use Committee (IACUC) at the California National Primate Research Center (Davis, CA). Subjects were housed at the California National Primate Research Center (Davis, CA), and surgeries were performed there. Subsequent tissue processing and analysis was performed at the Center for Neural Repair (University of California, San Diego, La Jolla, CA).
Lesion surgery. Monkeys were sedated with 1 mg ketamine per kg body weight intramuscularly and anesthetized with 1.5-2.5% isoflurane. The caudal half of the C5 dorsal lamina and the entire C6 dorsal lamina were removed. The dura was slit longitudinally along the midline and retracted gently. A surgical microknife was mounted on a stereotaxic arm positioned at the spinal midline midway between the C5 and C6 dorsal laminae. This rostrocaudal position corresponds to the C7 spinal cord segment. The stereotaxic manipulator was used to lower the blade through the entire dorsoventral extent of the spinal cord without severing the ventral artery. This initial cut established the medial position of the lesion. The surgeon then used microscissors to complete the lesion using microscopic observation to ensure lateral and ventral lesion completeness. Monkeys retained bowel, bladder, and autonomic function after SCI. Lesion reconstructions are shown in Supplementary Figure 13. Immunosuppression. All grafted subjects received a triple-therapy immunosuppressive regimen comprising mycophenolate mofetil (MMF; CellSept), tacrolimus (FK-506; ProGraf), and prednisone. Treatment began 1 d before grafting, and drugs were administered orally or through a nasogastric tube. In all subjects, the initial dose of prednisone was 2 mg per kg body weight per day and was reduced to 1 mg per kg body weight per day on the second day after transplantation. In Subjects 1-4, the initial dosage of MMF was 50 mg per kg body weight per day, and the initial dosage of FK-506 was 0.3 mg per kg per body weight per day. Treatment with both drugs was split into 2 doses (a.m. and p.m.). Initial dosages of MMF and FK-506 were increased to 100 mg per kg body weight per day and 1 mg per kg body weight per day, respectively, owing to poor graft survival in Subjects 1-4. Blood trough levels of MMF (target range, 3-6 µg/ml) and FK-506 (target range, 4-10 ng/ml) were assessed 1-3 times per week to adjust dosages. Immunosuppression continued until date of euthanization.
Grafting. Two weeks after the C7 right lateral hemisection, we grafted 20 million GFP-expressing human neural progenitor cells into the lesion site. This karyotypically stable cell line (566RSC-UBQT) was derived from the lower cervical and upper thoracic spinal cord of an 8-week-old fetus that was donated in accordance with National Institutes of Health and Food and Drug Administration guidelines 28 . As previously reported 29, 30 , the vast majority (94%) of these cells express nestin and are uncommitted to neuronal or glial lineage before transplantation. These cells are maintained, authenticated, and tested for mycoplasma by NeuralStem, Inc. Human NPCs were shipped at 4 °C while suspended at 20,000 cells per µl of a proprietary hibernation medium with overnight delivery. Subjects were sedated and anesthetized as described above, and the lesion site was re-exposed. Hibernation media were removed, and then human NPCs were suspended at 200,000 cells per µl of a two-part fibrin matrix (human fibrinogen, Sigma, F3879, 100 mg/ml; human thrombin, Sigma, T7009, 100 U/ml) containing a cocktail of growth factors: brain-derived neurotrophic factor (BDNF; 50 µg/ml, Peprotech, 452-02), neurotrophin-3 (NT-3; 50 µg/ml, Peprotech, 450-03), glial-cell-line-derived neurotrophic factor (GDNF; 10 µg/ml, Sigma, G1401), epidermal growth factor (EGF; 10 µg/ml, Sigma, E1257), basic fibroblast growth factor (bFGF; 10 µg/ml, Sigma, F0291), acidic fibroblast growth factor (aFGF; 10 µg/ml, Sigma, F5542), hepatocyte growth factor (HGF; 10 µg/ml, Sigma, H9661), insulin-like growth factor 1 (IGF-1; 10 µg/ml, Sigma, I8779), platelet-derived growth factor (PDGF-AA; 10 µg/ml, Peprotech, 100-13A), vascular endothelial growth factor (VEGF; 10 µg/ml; Peprotech, 100-20), and a calpain inhibitor (MDL28170; 50 µM, Sigma, M6690). For Subjects 3-9, immediately before the placement of cells into the lesion site, the surgical table was tilted to an approximately 30° angle (head upward). This temporarily drains CSF away from the lesion site, providing 5-15 min for surgeons to place the cells and for the liquid components of the fibrin matrix to form a gel that held the NPCs in the lesion site. After the gel formed, the dura, muscles and fascia, and skin were sutured closed in layers.
Corticospinal tracing. Corticospinal tract (CST) axons were traced in Subject 9 to assess regeneration into the graft. As previously described 20 , 6 weeks before euthanization, the subject was anesthetized and a craniotomy was performed to expose the left motor cortex. 300 nl of the anterograde neuronal tracer biotinylated dextran amine (BDA; 10,000 molecular weight, 10% in water; Thermo Fisher) was injected at each of 127 sites (59 different surface locations). These sites included motor cortex innervating regions of spinal cord controlling the hand, arm, trunk, leg, and foot.
Tissue processing. Subjects were euthanized 2-9 months after receiving human NPC grafts. Subjects were deeply anesthetized and transcardially perfused with a 4% solution of paraformaldehyde, and the spinal cord was dissected out of the spinal column. Spinal cord dura was removed, and the spinal cord was cut in the transverse plane into 1-or 1.5-cm-long blocks as described previously 27 . The block containing the lesion was cut into 30-µm-thick horizontal sections using a freezing microtome. Additional blocks of tissue were cut into 40-µm-thick transverse sections. In Subject 9, the tissue blocks immediately rostral and caudal to the lesion block were first partially cut (6 transverse sections that were 50 µm thick) using a vibratome; this method is more compatible with electron microscopy. The vibratome-cut sections were then immediately immunolabeled for green fluorescent protein (see below), and the remaining tissue in those blocks was cut on a microtome in the same fashion as the other spinal cords. Tissue sections were stored at -20 °C in tissue cryoprotectant solution (TCS; 25% glycerin (vol/vol) and 30% ethylene glycol (vol/vol) in 0.5 M phosphate buffer).
Fluorescent immunolabeling.
Transverse sections were pretreated with 50% methanol for 20 min at 22-24 °C, washed in Tris-buffered saline (TBS) and blocked for 1 h in TBS containing 5% normal donkey serum and 0.25% Triton X-100. Sections were incubated in primary antibodies against GFP (rabbit, Thermo Fisher no. 6455, 1:1,500); GFAP (chicken, Encor Bio no. CPCA-GFAP, 1:1,500, to label astrocytes); NeuN (mouse, Millipore MAB377, 1:1,000, to label mature neurons); class III β-tubulin (mouse, Promega G-7121, 1:1,000, to label immature and mature neurons); neurofilament lightchain (NF70, mouse, Millipore MAB1615, 1:300, to label immature axons); neurofilament unphosphorylated heavy-chain (SMI32, mouse, Covance no. SMI-32P, 1:2,000); neurofilament phosphorylated heavy-chain (NF200, mouse, Millipore MAB5262, 1:500); Ki-67 (rabbit, Abcam ab1666, 1:250, to label dividing cells); OLIG2 (rabbit, IBL no. 18953, 1:200, to label oligodendrocytes and MN precursors); OPALIN (mouse, Santa Cruz Biotechnology no. sc-374490, 1:200, to label myelinating oligodendrocytes); SOX9 (goat, R&D Systems no. AF3075, 1:1,000, to label astrocytes and ependymal cells); and HOMER1 (rabbit, Synaptic Systems no. 160003, 1:1,000, to label postsynaptic densities). BDA was detected with Alexa-Fluor 594-or Alexa-Fluor 568-conjugated streptavidin (Thermo Fisher S11226, 1:1,000). Sections were washed with TBS and then incubated in Alexa-Fluor 488-or Alexa-Fluor 594-conjugated anti-goat or anti-donkey secondary antibodies (Thermo Fisher A11055, A11058, SA5-10062, SA5-10064, 1:500) for 1 h and DAPI (Sigma D9542, 0.5 µg/µl, to label nuclei) for 5 min. Sections were washed with TBS, mounted on slides, and coverslipped with Mowiol mounting medium (http://cshprotocols.cshlp.org/content/2006/1/pdb.rec10255). All antibodies were used previously in monkeys and/or on the 566RSC-UBQT cell line 17, 27, 28 .
Electron microscopy. Some tissue sections from Subject 9 were analyzed with a combination of immunolabeling (for GFP) and electron microscopy (to identify synaptic structures). Sections were postfixed for 1 h in 0.1% glutaraldehyde in 0.1 M phosphate buffer (PB), and then endogenous peroxidase activity was quenched in 0.6% H 2 O 2 in TBS for 30 min. Sections were permeabilized in 50% ethanol in TBS for 30 min, incubated in 1% sodium borohydride in TBS for 30 min, and blocked in 5% horse serum and 0.025% Triton X-100 in TBS for 1 h. Sections were incubated for 3 nights in primary antibody (rabbit anti-GFP, Thermo Fisher no. A6455, 1:3,000 in blocking buffer). Sections were then incubated for 1 h in Vector Impress Poly-HRP secondary antibody (Vector no. MP-7401, 1:1 in TBS). Finally, a visible reaction product was developed in 0.05% diaminobenzidene, 0.04% nickel chloride, and 0.012% H 2 O 2 in TBS for approximately 4 min. Wet sections were next examined by light microscopy, and the portions containing visible reaction products within the spinal cord gray matter were trimmed and processed for ultrastructural studies. The trimmed sections were first immersed in a 1% osmium tetroxide solution (Ted Pella, Inc.), dehydrated in a graded series of ethanol, and immersed in 100% propylene oxide. Sections were next embedded in an epoxy resin using the Eponate 12 kit with DMP-30 as an accelerator (Ted Pella, Inc. no. 18010). Ultrathin sections were cut with thickness of 60-70 nm using an RMC Products PowerTome Ultramicrotome (Boeckeler Instruments), and the ultrathin sections were collected on formvar-coated one-hole copper grids. The sections were contrasted with uranyl acetate and lead citrate. The ultrathin sections were finally examined in a JEOL 100 CX transmission electron microscope. Neuronal processes containing electron-dense reaction products were photographed at a magnification of 7,200×, and images were captured on an electron microscope film (Electron Microscopy Sciences).
Image acquisition. Epifluorescent images were captured using an Optronics Microfire A/R digital camera (http://www.optronics.com) or a Keyence BZ-X710 all-in-one microscope and camera. Confocal images were captured with an Olympus Fluoview FV1000 confocal microscope (http://www.olympusamerica. com) set for sequential scanning. For publication, images were processed uniformly for optimal brightness and contrast using Adobe Photoshop CS5 (Adobe Systems, San Jose, CA). Images intended for quantification (see below) were not modified in this fashion. Composites of multiple focal planes were constructed either in Adobe Photoshop CS5 or ImageJ 1.48v (Wayne Rasband, National Institutes of Health; http://rsb.info.nih.gov/ij/).
Quantification of graft volume, neural cell density, and axon number. Graftderived cells were quantified in confocal image stacks by counting individual cells labeled with GFP and NeuN within a fixed rectangular region of interest (ROI) drawn with ImageJ. All cells within the ROI were counted, and the area was quantified. For each monkey, 5-14 image stacks (spread in a grid across the graft) were quantified (a mean of 766 ± 100 individual cells per subject). Cell density was estimated via dividing the number of cells by the ROI volume. Additional estimates of the proportion of cells in the graft coexpressing NeuN, OLIG2, SOX9, or Ki-67 were made under epifluorescent illumination using StereoInvestigator (MicroBrightfield, http://www.mbfbioscience.com). Graft area was measured in horizontal tissue sections (1:12 series; a mean of 14.4 ± 0.9 sections per monkey) under epifluorescent illumination using StereoInvestigator. Graft volume was estimated as (summed area across all sections) × (average section thickness) × (inverse of the sampling frequency).
Total graft-derived cell counts were estimated through multiplying the cell density by the graft volume. The number of GFP-labeled axons was quantified under epifluorescent illumination using StereoInvestigator (MicroBrightfield; http://www.mbfbioscience.com). In horizontal tissue sections (1:12 series), a transverse line was drawn 2 mm caudal to the edge of the graft using a 4× objective. Axons that intersected the line were marked and counted using a 60× objective, and the total axon number per subject was estimated by multiplying the axon count by the inverse of the sampling frequency.
Functional testing. Functional recovery was evaluated weekly throughout the study in an open-field task previously developed by our group to assess general motor function and overground locomotion, climbing and object manipulation [38] [39] [40] . Behavioral assessments in this open field were typically performed live with two observers: one videotaping the session (R.M. or S.H.), and one recording behavioral observations on the scoring sheet (E.S. or J.C.B.). Alternatively, sessions were scored directly from the video; the videos were also used to confirm live scoring results. Inter-rater reliability was evaluated periodically, and high levels of agreement were obtained (E.S. and J.C.B.). All assessments were performed without knowledge of group inclusion, as the observers had no way of knowing which monkeys had surviving transplants. Monkeys entered an open field testing enclosure (10 feet long × 6 feet wide × 7 feet high) and had access to four ascending perches to reach a food reward placed inside a Kong (a hollow rubber toy filled with raisins, apple pieces, peanuts, dry fruit, etc.; Kong Co., Golden CO) positioned on the highest perch. Locomotor activity was evaluated while the monkeys traversed the perches as well as the floor of the open cage. Climbing was assessed during retrieval of similar food objects placed in cups hanging at various heights (1.5, 2.7, 3.5, 4.3, and 4.7 feet) along the front of the cage. Object manipulation was assessed during manipulation of the Kong toy and during the consumption of a large food item to encourage bimanual manipulation (for example, an apple or orange; see Supplementary Fig. 10) . A modified 72-point scale was used and assigned points for behavioral function. The object manipulation subscale had 22 points and was used to assess forelimb function while manipulating objects and to score posture, method used to support object (i.e., volar versus nonvolar surface of hand), joint and finger movements, digit 1 opposition, and pincer grasp. We compared the level of functional performance of monkeys with surviving grafts (n = 5) and nonsurviving grafts (n = 4). Because groups were established after euthanization, experimenters were blind to group membership. Although monkeys survived for differing lengths of time after grafting, the performance of all monkeys reached an asymptote during their survival period ( Supplementary  Fig. 10 ), as assessed by modified moving averages. Accordingly, we calculated the maximal score for each monkey during the period of asymptotic function (see Supplementary Figs. 10-12 ).
Statistical analysis and reproducibility. All immunohistochemical reactions were performed at least twice with similar results. Graft cell densities, sizes, and axon counts were analyzed with Matlab 2010b (MathWorks). The 'Corrcoef ' function was used to calculate the correlation (R 2 ) of these variables with survival time and the P values of those correlations. Functional data were analyzed by applied biostatisticians (J.R.H. and A.R.F.) who were blinded to experimental conditions. Nonparametric tests on single (univariate) outcome measures were executed using generalized linear modeling (GZLM), and significance was assessed using the Wald chi-square test. To assess the multivariate effect of behavioral outcome measures, we integrated these data using a modern data-driven analytics approach in which a combined behavioral endpoint was derived through a multidimensional pattern detector (nonlinear principalcomponent analysis; NL-PCA) in an unsupervised manner and blinded to experimental condition. Our analytical workflow involved two distinct stages of statistical analysis (Supplementary Fig. 12 ): stage 1, multidimensional endpoint description using PCA and validation of PC loading patterns; and stage 2, hypothesis testing using the validated multidimensional pattern (PC1) as the primary combinatorial endpoint. Stage 1 pattern detection was assessed using multidimensional endpoint variable integration into PC1, which was followed by examination of variance explained and PC loadings for statistical and face validity, respectively. Once that single, PCA-weight-combined endpoint axis (PC1) was deemed reproducible and valid, we applied the PC weights to derive the unique PC score for each monkey at each time point and rigorously validated these using previously established statistical decision rules [60] [61] [62] [63] . The PC scores were then plotted over time, and if a monkey's recovery time did not reach 21 weeks, the last observed PC score for that monkey was carried forward to 21 weeks using techniques consistent with best practices from the clinical literature 64 . Only after PC scores were mathematically derived for each subject and time point (Supplementary Fig. 12a-c) did we move to the stage 2 hypothesis testing (Supplementary Fig. 12d,e) . Hypothesis testing used PC scores as the primary endpoint to assess impact of graft condition on behavioral outcome. A linear mixed model (LMM; IBM SPSS 'Mixed' subcommand) was then applied to assess group differences in PC1 scores over time. This variance components approach is resistant to errors caused by missing data and independence violations that would otherwise undermine the validity of repeated-measures ANOVA in this context. Prior work from our group and others have demonstrated that PCA is robust and stable when used in this context (even with a small sample size) 27, 41 as long as the variance explained by PC1 is high and the communalities are high. These statistical features indicate that the combined information provided by the optimally weighted combination of variables (PC1) is greater than the sum of the raw endpoint variables regardless of sample size 62 . The statistical analysis plan was carried out by the project's independent statistical analysis core (blinded to treatment until the final analysis step). The goal was to maximize information gain in the most transparent and statistically appropriate manner given the costs and the desire to limit subject numbers in primate studies 65 . All analyses were carried out in SPSS v.23 (IBM). PC loadings were considered significant at |0.4|. Significance for GZLM and LMM was assessed at P < 0.05.
Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
Data availability. The data that support the findings of this study are available from the corresponding author upon reasonable request.
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For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided Describe the software used to analyze the data in this study.
StereoInvestigator and NIH ImageJ were used for image analysis as described in Methods. Adobe Photoshop CS5 was used for image brightness and contrast adjustment. SPSS v.23 and Matlab 2010b were used for statistical analyses as described in Methods.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
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566-RSC cells were a gift from NeuralStem, Inc. Requests for aliquots of these cells should be directed toward that company.
